Value of a novel sGC stimulant Vericygide in the treatment of heart failure
Objective:To investigate the value of vericypiac,a novel soluble guanylate cyclase(sGC)stimulator,in the treatment of heart failure(HF).Methods:From October 2022 to June 2023,60 patients with HF admitted to our hospital were divided into Vericygua group and control group by machine digital table method,with 30 cases in each group.The control group received conventional anti-HF treatment,and the vericigua group received oral vericigua on the basis of the control group,all of which lasted for 3 months.The effects of improving cardiac function,treating ventricular remodeling index,cardiac function and incidence of adverse reactions were compared between the two groups.Results:The improvement effect of heart function in vericiquide group was 93.33%,which was higher than that in control group(73.33%,P<.05).LVEF and 6MWT of vericygua group were higher than those of control group,LVESV,LVEDD and NT-ProBNP of Vericygua group were lower than those of control group(P<0.05).Conclusion:Vericygide,a new type of sGC stimulator,can improve the cardiac function and exercise endurance of HF patients,and reduce the level of NT-ProBNP.
Soluble guanylate cyclase stimulatorVeliciquaHeart failureCardiac function improvement effect
NETL
NSTL
万方数据
维普
